Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health Lumizyme Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentModa HealthPolicy M-0079

    Lumizyme (alglucosidase alfa) (Intravenous)

    Customize your policy alerts

    Sign up for Moda Health Policy M-0079 alerts

    Get alerted when Policy M-0079 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Moda Health prior authorization, dosing limits, medical necessity criteria, renewal conditions, and billing codes for intravenous Lumizyme (alglucosidase alfa) for treatment of Pompe disease.

    Policy Summary
    PayerModa Health
    PolicyLumizyme (alglucosidase alfa) (Intravenous)
    Policy CodePolicy M-0079
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization and submit baseline age-appropriate clinical measures and confirmatory diagnostic evidence (GAA enzyme deficiency or biallelic pathogenic GAA variants).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsinitial prior authorization validity
    230max HCPCS units/14 days
    20 mg/kg q2wrecommended dosing
    J0221HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    E74.02
    covered diagnosis

    Coverage Criteria for Lumizyme (alglucosidase alfa)

    Initial Therapy

    Prior authorization validity is provided when ALL of the following are met:

    Initial Approval Criteria: 1) For groups in scope for the Site of Care (SOC) specialty infusion program, all program requirements are met; AND 2) Documented baseline age-appropriate values for one or more of the following: infantile-onset disease measures (muscle weakness, motor function, respiratory function, cardiac involvement, percent predicted FVC, and/or 6-minute walk test [6MWT]) OR late-onset disease measures (FVC and/or 6MWT). Note: very young members for whom FVC or 6-MWT are unsuitable will be reviewed case-by-case; AND 3) Diagnosis of Pompe disease confirmed by either deficiency of acid alpha-glucosidase (GAA) enzyme activity OR detection of biallelic pathogenic or likely pathogenic variants in the GAA gene; AND 4) Therapy will not be used in combination with other enzyme replacement therapies.

    Supports FDA-approved and compendia indications for Pompe disease.

    Continuation/Renewal

    Prior authorization may be renewed when ALL of the following are met:

    Renewal Criteria: 1) Member continues to meet the universal and indication-specific criteria from initial approval (section III); AND 2) Absence of unacceptable toxicity from the drug (examples: hypersensitivity/anaphylaxis, infusion-associated reactions, immune-mediated reactions, acute cardiorespiratory failure, cardiac arrhythmia during general anesthesia); AND 3) Member is being monitored for antibody formation (including neutralizing antibodies); AND 4) Member has demonstrated stabilization or improvement compared to pretreatment age-appropriate baseline in specified clinical measures: for infantile-onset disease—muscle weakness, motor function, respiratory function, cardiac involvement, FVC, and/or 6-MWT; OR for late-onset disease—stabilization or improvement in FVC and/or 6-MWT.

    Dosage/Administration

    Dosing: Administer alglucosidase alfa (Lumizyme) 20 mg/kg IV every 2 weeks; billing unit = 10 mg per HCPCS J0221 with a maximum of 230 billable units per 14 days (equivalent to 2,300 mg per 14 days).

    Use in combination with other enzyme replacement therapies is not allowed. This therapy must not be administered concurrently with any other enzyme replacement treatment for Pompe disease.

    Prior authorization will not be continued if there is unacceptable toxicity or a lack of clinical benefit. Examples of unacceptable toxicity include hypersensitivity/anaphylaxis, infusion-associated reactions (e.g., fever, chills, flu-like illness, rash/urticaria, pruritus), immune-mediated reactions, acute cardiorespiratory failure, or cardiac arrhythmia during general anesthesia. Lack of clinical benefit is defined as failure to stabilize or improve compared to pretreatment age-appropriate baseline measures (e.g., motor function, respiratory function, FVC, 6-minute walk test).

    Confirmation of Pompe disease

    Confirmation of Pompe disease: Detection of biallelic pathogenic or likely pathogenic variants in the GAA gene qualifies as confirmatory diagnostic evidence for coverage (alternative confirmatory evidence: deficiency of GAA enzyme activity).

    Billing, HCPCS, NDC, and Diagnosis Codes

    Covered HCPCS CodesHCPCSCovered
    J0221Injection, alglucosidase alfa, (lumizyme), 10 mg; 1 billable unit = 10 mg
    NDCNDC
    58468-0160-xxLumizyme 50 mg single-dose vial for injection
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    E74.02Pompe disease
    HCPCS unit limit
    HCPCS unit limit230 billable units every 14 days
    Unit definition1 billable unit = 10 mg (HCPCS J0221)
    Billing intervalLimit applies per 14-day period

    Provider Requirements, Documentation, and Denial Risks

    Prior Authorization

    Obtain prior authorization for 12 months and submit baseline clinical measures

    Prior authorization is required for Lumizyme and will be issued initially for 12 months (365 days). Requests for authorization must include the baseline clinical measures specified in the initial approval criteria (age‑appropriate baseline values such as FVC, 6‑minute walk test, muscle/respiratory/cardiac measures) and any Site of Care specialty infusion program requirements when applicable.

    • Initial authorization duration: 12 months (365 days).
    • Include documented baseline age-appropriate clinical measures as specified under Initial Approval Criteria.
    • For groups in scope of the Site of Care (SOC) specialty infusion program, include documentation that program requirements are met.
    Step Therapy

    Do not combine with other enzyme replacement therapies

    Lumizyme must not be used in combination with other enzyme replacement therapies; concurrent use with another ERT is a contraindicated combination under the universal criteria.

    Indications Covered by Policy

    Confirmation of Pompe disease

    Confirmation of Pompe disease: Detection of biallelic pathogenic or likely pathogenic variants in the GAA gene qualifies as confirmatory diagnostic evidence for coverage (alternative confirmatory evidence: deficiency of GAA enzyme activity).

    Background on Pompe Disease and Therapy

    Pompe disease (acid alpha-glucosidase [GAA] deficiency) is an inherited metabolic disorder treated with enzyme replacement therapy, specifically intravenous alglucosidase alfa (Lumizyme). Diagnosis is confirmed by either a deficiency of GAA enzyme activity or detection of biallelic pathogenic or likely pathogenic variants in the GAA gene; infantile-onset disease may be rapidly suspected after positive newborn screening but should be confirmed by molecular testing or measurement of GAA activity in another tissue.

    Definitions and Diagnostic Criteria

    Pompe disease diagnosis
    Confirmatory criteria (enzyme)Deficiency of acid alpha-glucosidase (GAA) enzyme activity
    Confirmatory criteria (genetic)Detection of biallelic pathogenic or likely pathogenic variants in the GAA gene by molecular genetic testing
    Infantile-onset noteInfantile-onset may be rapidly suspected after positive newborn screening; confirm with molecular testing or GAA activity in another tissue
    Policy Summary
    PayerModa Health
    PolicyLumizyme (alglucosidase alfa) (Intravenous)
    Policy CodePolicy M-0079
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization and submit baseline age-appropriate clinical measures and confirmatory diagnostic evidence (GAA enzyme deficiency or biallelic pathogenic GAA variants).
    SourceLink
    On This Page
    Coverage Criteria for Lumizyme (alglucosidase alfa)Billing, HCPCS, NDC, and Diagnosis CodesProvider Requirements, Documentation, and Denial RisksIndications Covered by PolicyMember Eligibility RequirementsBackground on Pompe Disease and TherapyDefinitions and Diagnostic Criteria
    • Requests must confirm Lumizyme will not be given alongside any other enzyme replacement therapy.
    Documentation Required

    Submit baseline age-appropriate clinical measures at initiation

    At initiation, provide documented baseline age-appropriate values such as infantile-onset measures (muscle weakness, motor function, respiratory function, cardiac involvement, percent predicted FVC, and/or 6‑minute walk test) or late-onset measures (FVC and/or 6‑minute walk test) as part of the authorization request.

    • Include specific baseline measures appropriate to the member's age and disease onset (infantile vs late-onset).
    • If FVC or 6‑MWT are unsuitable (very young members), note that requests will be reviewed case-by-case.
    Denial Risk

    Diagnosis confirmation and renewal failures are potential denial triggers

    Authorization may be denied if the diagnosis of Pompe disease is not confirmed by either deficient GAA enzyme activity or detection of biallelic pathogenic/likely pathogenic GAA variants, or if renewal criteria such as absence of unacceptable toxicity, antibody monitoring, and clinical benefit are not met.

    • Lack of confirmatory diagnostic evidence (GAA enzyme deficiency or biallelic pathogenic GAA variants) can trigger denial.
    • Failure to meet renewal requirements — e.g., unacceptable toxicity, no monitoring for antibodies, or lack of stabilization/improvement compared to pretreatment baseline — may result in denial at renewal.